Advertisement
HomeCollectionsCbl
IN THE NEWS

Cbl

FEATURED ARTICLES
BUSINESS
January 3, 1996
Chesapeake Biological Laboratories yesterday announced a strategic alliance with a California firm to develop, manufacture and distribute generic injectable pharmaceuticals.With headquarters in Owings Mills and a plant in the Seton Industrial Park in Baltimore, CBL brings experience in manufacturing to its deal with Pasadena Research Laboratories Inc. of San Clemente, Calif. PRL brings a distribution network.CBL is looking for city and state help to add a 55,000-square-foot facility to its existing 15,000 square-foot building at Seton Park, said Chief Financial Officer Jack Janssen.
ARTICLES BY DATE
NEWS
January 4, 2004
Tenn. company buys Harford Mall for $71 million Harford County's only enclosed mall and the adjacent shopping annex have been purchased by a Chattanooga, Tenn., real estate company for $71 million. Harford Mall, built in Bel Air in 1973, is one of the smaller regional centers in the Baltimore area - a single-story building with 500,000 square feet of space. It is anchored by Hecht's and Sears and is about 95 percent full, according to CBL & Associates Properties Inc., the Tennessee company that bought the properties from affiliates of Kimco Realty Corp.
Advertisement
BUSINESS
By Mark Guidera and Mark Guidera,SUN STAFF | January 10, 1998
Chesapeake Biological Laboratories Inc. said yesterday that it has expanded a production agreement with Sheffield Pharmaceuticals Inc. for a new inhaler for people with asthma and other respiratory diseases.Joseph A. Twist, a spokesman for Baltimore-based CBL, said the deal broadens an alliance formed in May 1996 in which CBL helped St. Louis-based Sheffield develop an inhaler loaded with albuterol sulfate, a medication commonly prescribed for asthma.CBL contracts with biotechnology and pharmaceutical companies to produce sterile batches of their drugs for clinical trials and marketing.
BUSINESS
By Jamie Smith Hopkins and Jamie Smith Hopkins,SUN STAFF | January 1, 2004
Harford County's only enclosed mall and the adjacent shopping annex have been purchased by a Chattanooga, Tenn., real estate company for $71 million. Harford Mall, built in Bel Air in 1973, is one of the smaller regional centers in the Baltimore area - a single-story building with 500,000 square feet of space. It's anchored by Hecht's and Sears and is about 95 percent full, according to CBL & Associates Properties Inc., the Tennessee company that bought the properties from affiliates of Kimco Realty Corp.
BUSINESS
By M. William Salganik and M. William Salganik,SUN STAFF | August 11, 2000
Posting its fifth straight quarter in the black, Chesapeake Biological Laboratories Inc. yesterday recorded earnings of $35,000, or 1 cent a share, for the three months ended June 30, the first quarter of CBL's fiscal year. The earnings figure fell short of the $112,000, or 2 cents a share, earned in the year-ago quarter. Revenue rose 13 percent to $2.8 million. The Baltimore company is a contract pharmaceutical and biotechnology manufacturer. The revenue growth indicates new customers and higher volume from existing customers, said Thomas P. Rice, president and chief executive officer.
BUSINESS
By Jamie Smith Hopkins and Jamie Smith Hopkins,SUN STAFF | January 1, 2004
Harford County's only enclosed mall and the adjacent shopping annex have been purchased by a Chattanooga, Tenn., real estate company for $71 million. Harford Mall, built in Bel Air in 1973, is one of the smaller regional centers in the Baltimore area - a single-story building with 500,000 square feet of space. It's anchored by Hecht's and Sears and is about 95 percent full, according to CBL & Associates Properties Inc., the Tennessee company that bought the properties from affiliates of Kimco Realty Corp.
BUSINESS
By Julie Bell and Julie Bell,SUN STAFF | February 19, 2002
Chesapeake Biological Laboratories Inc. cut the ribbon yesterday on a $16 million plant where it will put smallpox vaccine into vials, the final step in a manufacturing process designed to stockpile enough of the vaccine to protect every U.S. civilian. The southwest Baltimore contract manufacturer, a subsidiary of Winnipeg, Manitoba-based Cangene Corp., built the 12,000-square-foot plant under a shroud of secrecy in just three months - years faster than usual for biotechnology plant construction.
NEWS
July 23, 1997
Chesapeake Biological Laboratories Inc.'s earnings per share were inaccurately reported in yesterday's editions. CBL reported loss of 1.7 cents per share in the first quarter ended June 30, compared with a loss of 2.2 cents per share in the same period last year.The Sun regrets the errors.Pub Date: 7/23/97
BUSINESS
By Mark Guidera and Mark Guidera,SUN STAFF | December 23, 1998
Chesapeake Biological Laboratories Inc., a Baltimore-based biotechnology manufacturing contractor, named former pharmaceutical industry executive Thomas P. Rice as its president and chief executive officer yesterday.The company said Rice would replace John C. Weiss III, CBL's president since May 1996, who has resigned.William P. Tew, CBL's chairman of the board, said Rice, a member of the company's board of directors since 1997, will be a strong addition to the company's management team."He brings with him a wealth of knowledge and experience in the pharmaceutical industry, which will be a great asset to CBL as it continues its transition to a larger-scale commercial producer of sterile, injectable bio-pharmaceutical and pharmaceutical products," Tew said.
BUSINESS
By Mark Guidera and Mark Guidera,SUN STAFF | August 12, 1997
An article in Monday's editions incorrectly stated the year that Chesapeake Biological Laboratories Inc. expects its new commercial production facility in Baltimore to be operational. The company expects it to open in early 1998.The Sun regrets the error.In a thriving manufacturing district of South Baltimore, John C. Weiss III surveys construction workers who are transforming a former food distribution warehouse into a state-of-the-art biotechnology production plant.Weiss, president of Chesapeake Biological Laboratories Inc., expects the facility to provide the manufacturing muscle needed to grab a larger share of the booming business among drug companies hiring outside contractors to make batches of their human and animal products for clinical trials and commercialization.
BUSINESS
By Julie Bell and Julie Bell,SUN STAFF | February 19, 2002
Chesapeake Biological Laboratories Inc. cut the ribbon yesterday on a $16 million plant where it will put smallpox vaccine into vials, the final step in a manufacturing process designed to stockpile enough of the vaccine to protect every U.S. civilian. The southwest Baltimore contract manufacturer, a subsidiary of Winnipeg, Manitoba-based Cangene Corp., built the 12,000-square-foot plant under a shroud of secrecy in just three months - years faster than usual for biotechnology plant construction.
BUSINESS
By M. William Salganik and M. William Salganik,SUN STAFF | August 11, 2000
Posting its fifth straight quarter in the black, Chesapeake Biological Laboratories Inc. yesterday recorded earnings of $35,000, or 1 cent a share, for the three months ended June 30, the first quarter of CBL's fiscal year. The earnings figure fell short of the $112,000, or 2 cents a share, earned in the year-ago quarter. Revenue rose 13 percent to $2.8 million. The Baltimore company is a contract pharmaceutical and biotechnology manufacturer. The revenue growth indicates new customers and higher volume from existing customers, said Thomas P. Rice, president and chief executive officer.
BUSINESS
By Mark Guidera and Mark Guidera,SUN STAFF | December 23, 1998
Chesapeake Biological Laboratories Inc., a Baltimore-based biotechnology manufacturing contractor, named former pharmaceutical industry executive Thomas P. Rice as its president and chief executive officer yesterday.The company said Rice would replace John C. Weiss III, CBL's president since May 1996, who has resigned.William P. Tew, CBL's chairman of the board, said Rice, a member of the company's board of directors since 1997, will be a strong addition to the company's management team."He brings with him a wealth of knowledge and experience in the pharmaceutical industry, which will be a great asset to CBL as it continues its transition to a larger-scale commercial producer of sterile, injectable bio-pharmaceutical and pharmaceutical products," Tew said.
BUSINESS
By Mark Guidera and Mark Guidera,SUN STAFF | July 25, 1998
Chesapeake Biological Laboratories Inc. said yesterday that its net loss widened to $392,000, or 7 cents a share, in its first quarter ended June 30, compared with a $75,000 loss, or 2 cents a share, in the first quarter last year.The company said revenue also declined for the first three months to $1.1 million, compared with $1.7 million in the year-earlier quarter.CBL's president, John C. Weiss III, said the increased loss was expected.The Baltimore-based provider of contract manufacturing and testing services to the biotechnology and pharmaceutical industries attributed most of the loss to the fact that a former top customer, Allergan Inc., terminated its use of CBL's services, Weiss said.
BUSINESS
January 22, 1998
Chesapeake Biological Laboratories Inc. said yesterday that it has won a contract to formulate, fill and package two experimental fluids being developed for protecting hearts during transplant and bypass surgery.The contract was struck with LXR Biotechnology Inc. of Richmond, Calif.The companies declined to disclose financial terms of the deal.Joseph A. Twist, a CBL spokesman, said the deal calls for the Baltimore-based biotechnology contractor to provide batches of HK-Cardiosol and CP-Cardiosol for clinical trials.
BUSINESS
By Mark Guidera and Mark Guidera,SUN STAFF | January 10, 1998
Chesapeake Biological Laboratories Inc. said yesterday that it has expanded a production agreement with Sheffield Pharmaceuticals Inc. for a new inhaler for people with asthma and other respiratory diseases.Joseph A. Twist, a spokesman for Baltimore-based CBL, said the deal broadens an alliance formed in May 1996 in which CBL helped St. Louis-based Sheffield develop an inhaler loaded with albuterol sulfate, a medication commonly prescribed for asthma.CBL contracts with biotechnology and pharmaceutical companies to produce sterile batches of their drugs for clinical trials and marketing.
BUSINESS
By Mark Guidera and Mark Guidera,SUN STAFF | July 25, 1998
Chesapeake Biological Laboratories Inc. said yesterday that its net loss widened to $392,000, or 7 cents a share, in its first quarter ended June 30, compared with a $75,000 loss, or 2 cents a share, in the first quarter last year.The company said revenue also declined for the first three months to $1.1 million, compared with $1.7 million in the year-earlier quarter.CBL's president, John C. Weiss III, said the increased loss was expected.The Baltimore-based provider of contract manufacturing and testing services to the biotechnology and pharmaceutical industries attributed most of the loss to the fact that a former top customer, Allergan Inc., terminated its use of CBL's services, Weiss said.
BUSINESS
By Mark Guidera and Mark Guidera,SUN STAFF | November 28, 1997
Vicky Distance has neither a science nor technical background, but she does have an interest in the nuts and bolts of high-tech machinery. That curiosity, and the technical acumen she displayed on tests, may have landed her a career in the state's burgeoning biotechnology sector.The East Baltimore resident is one of nine Empowerment Zone residents chosen from a pool of 117 applicants to be trained in laboratory and other technical skills for Chesapeake Biological Laboratories Inc. (CBL).The program she'll be trained in and employed under is a novel venture among CBL, the Johns Hopkins University School of Medicine and Baltimore City Community College.
BUSINESS
By Mark Guidera and Mark Guidera,SUN STAFF | August 12, 1997
An article in Monday's editions incorrectly stated the year that Chesapeake Biological Laboratories Inc. expects its new commercial production facility in Baltimore to be operational. The company expects it to open in early 1998.The Sun regrets the error.In a thriving manufacturing district of South Baltimore, John C. Weiss III surveys construction workers who are transforming a former food distribution warehouse into a state-of-the-art biotechnology production plant.Weiss, president of Chesapeake Biological Laboratories Inc., expects the facility to provide the manufacturing muscle needed to grab a larger share of the booming business among drug companies hiring outside contractors to make batches of their human and animal products for clinical trials and commercialization.
Baltimore Sun Articles
|
|
|
Please note the green-lined linked article text has been applied commercially without any involvement from our newsroom editors, reporters or any other editorial staff.